BACKGROUND: Modulation of midbrain dopamine neurons by nicotinic acetylcholine receptors (nAChRs) plays an important role in behavior, cognition, motivation, and reward. Specifically, nAChRs containing beta2 subunits (beta2-nAChRs) switch dopamine cells from a resting to an excited state. However, how beta2-nAChRs can be modulated and thereby how dopamine firing activity is affected remains elusive. Because changes in dopamine cell activity are reflected in the dynamics of microcircuits generating altered responses to stimuli and inputs, factors regulating their state are fundamental. Among these, endogenous ligands to the nuclear receptor-transcription factor peroxisome proliferator-activated receptors type-alpha (PPARalpha) have been recently found to suppress nicotine-induced responses of dopamine neurons. METHODS: We used both in vitro and in vivo electrophysiological techniques together with behavioral analysis to investigate on the effects of modulation of PPARalpha in Sprague-Dawley rat and C57BLJ/6 mouse dopamine neurons and their interactions with beta2-nAChRs. To this aim, we took advantage of a selective reexpression of beta2-nAChR exclusively in dopamine cells by stereotaxically injecting a lentiviral vector in the mouse ventral tegmental area. RESULTS: We found that activation of PPARalpha decreases in vitro both dopamine cell activity and ventral tegmental area net output through negative modulation of beta2-nAChRs. Additionally, PPARalpha activation in vivo reduces both the number of spontaneously active dopamine neurons and nicotine-induced increased locomotion. CONCLUSIONS: Our combined findings suggest PPARalpha ligands as important negative modulators of beta2-nAChRs on dopamine neurons. Thus, PPARalpha ligands might prove beneficial in treating disorders in which dopamine dysfunction plays a prominent role, such as schizophrenia and nicotine addiction. Copyright 2010 Society of Biological Psychiatry. All rights reserved.
BACKGROUND: Modulation of midbrain dopamine neurons by nicotinic acetylcholine receptors (nAChRs) plays an important role in behavior, cognition, motivation, and reward. Specifically, nAChRs containing beta2 subunits (beta2-nAChRs) switch dopamine cells from a resting to an excited state. However, how beta2-nAChRs can be modulated and thereby how dopamine firing activity is affected remains elusive. Because changes in dopamine cell activity are reflected in the dynamics of microcircuits generating altered responses to stimuli and inputs, factors regulating their state are fundamental. Among these, endogenous ligands to the nuclear receptor-transcription factor peroxisome proliferator-activated receptors type-alpha (PPARalpha) have been recently found to suppress nicotine-induced responses of dopamine neurons. METHODS: We used both in vitro and in vivo electrophysiological techniques together with behavioral analysis to investigate on the effects of modulation of PPARalpha in Sprague-Dawley rat and C57BLJ/6 mousedopamine neurons and their interactions with beta2-nAChRs. To this aim, we took advantage of a selective reexpression of beta2-nAChR exclusively in dopamine cells by stereotaxically injecting a lentiviral vector in the mouse ventral tegmental area. RESULTS: We found that activation of PPARalpha decreases in vitro both dopamine cell activity and ventral tegmental area net output through negative modulation of beta2-nAChRs. Additionally, PPARalpha activation in vivo reduces both the number of spontaneously active dopamine neurons and nicotine-induced increased locomotion. CONCLUSIONS: Our combined findings suggest PPARalpha ligands as important negative modulators of beta2-nAChRs on dopamine neurons. Thus, PPARalpha ligands might prove beneficial in treating disorders in which dopamine dysfunction plays a prominent role, such as schizophrenia and nicotine addiction. Copyright 2010 Society of Biological Psychiatry. All rights reserved.
Authors: Ana B Ropero; Pablo Juan-Picó; Alex Rafacho; Esther Fuentes; F Javier Bermúdez-Silva; Enrique Roche; Ivan Quesada; Fernando Rodríguez de Fonseca; Angel Nadal Journal: J Endocrinol Date: 2008-11-18 Impact factor: 4.286
Authors: Andreas Artmann; Gitte Petersen; Lars I Hellgren; Julie Boberg; Christian Skonberg; Christine Nellemann; Steen Honoré Hansen; Harald S Hansen Journal: Biochim Biophys Acta Date: 2008-02-12
Authors: Asti Jackson; Deniz Bagdas; Pretal P Muldoon; Aron H Lichtman; F Ivy Carroll; Mark Greenwald; Michael F Miles; M Imad Damaj Journal: Neuropharmacology Date: 2017-03-07 Impact factor: 5.250
Authors: Kenneth A Perkins; Joshua L Karelitz; Valerie C Michael; Margaret Fromuth; Cynthia A Conklin; K N Roy Chengappa; Chris Hope; Caryn Lerman Journal: Nicotine Tob Res Date: 2015-04-20 Impact factor: 4.244
Authors: Maria Scherma; Anna Lisa Muntoni; Miriam Melis; Liana Fattore; Paola Fadda; Walter Fratta; Marco Pistis Journal: Psychopharmacology (Berl) Date: 2016-01-04 Impact factor: 4.530